Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $55.2652W HIGH $130.05
Volume
1.31 M
Value Traded
43.68 M
Short % Float
14.12%
+2.32%Week
-2.23%1 Month
+1.81%3 Month
+26.96%6 Month
+77.24%5 Year
+125.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.35 B
EPS (TTM)
-3.60
P/E Ratio
-
Ent. Value
7.84 B
Total Shares
83.14 M
Float Shares
74.59 M
Insiders
10.29%
Institutions
108.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KYMR Catalyst Timeline
Dated clinical, regulatory and corporate events for Kymera Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kymera Therapeutics, Inc.
563Total events
19Upcoming
79Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteKT-621Trial
Enrollment completed in BROADEN2 Phase 2b AD trial
atopic dermatitissource ↗
▲Enrollment CompleteKT-621Trial
Enrollment completed in Phase 2b study of KT-621 in atopic dermatitis
atopic dermatitissource ↗
◆Management ChangeCorporate
Appointment of Elizabeth Laws as SVP, Global Program Team Leader for KT-621
▲Enrollment CompleteKT-621Trial
Completed enrollment in BROADEN2 Phase 2b trial of KT-621 in atopic dermatitis
moderate to severe atopic dermatitissource ↗
▲Oral PresentationKT-621Presentation
Oral presentation of Phase 1 data for KT-621 in healthy Japanese adults at JDA Annual Meeting
Healthy Japanese adultssource ↗
▲First Patient DosedSAR447971Trial
First participant dosed in Phase 1 trial of KT-485
hidradenitis suppurativasource ↗
▲Milestone PaymentSAR447971Corporate
$20 million milestone payment from Sanofi triggered by first patient dosing
◆Poster PresentationKT-579Presentation
New data on KT-579 in lupus models at EULAR and FOCIS
lupussource ↗
◆Primary CompletionKT-474Trial
Estimated primary completion for ADVANTA trial (AD) in mid-2026
Atopic dermatitissource ↗
▲Enrollment CompleteKT-621Trial
Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial
atopic dermatitissource ↗
▲Trial InitiationSAR447971Trial
Sanofi initiated first-in-human Phase 1 trial of KT-485
hidradenitis suppurativasource ↗
▲Oral PresentationKT-621Presentation
Presented KT-621 Phase 1 results in healthy Japanese adults at JDA Annual Meeting
atopic dermatitissource ↗
◆Oral PresentationPresentation
RBC Capital Markets 2026 Global Healthcare Conference fireside chat
◆Oral PresentationKT-621Presentation
Late-breaking oral presentation of Phase 1b atopic dermatitis data at SID 2026
atopic dermatitissource ↗
▲Poster PresentationKT-579Presentation
Poster presentation at DDW 2026: Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates Robust Anti-inflammatory Activity and Disease Modulation in Preclinical In Vivo Models of Inflammatory Bowel Disease
Inflammatory Bowel Diseasesource ↗
◆Oral PresentationKT-621Presentation
Late-breaking oral presentation at SID Annual Meeting on STAT6 degradation in AD lesional skin
atopic dermatitissource ↗
◆Poster PresentationKT-579Presentation
New data on KT-579 in IBD models at DDW
inflammatory bowel diseasesource ↗
▲Fast Track DesignationKT-621Designation
FDA granted Fast Track designation for KT-621 in moderate to severe eosinophilic asthma
moderate to severe eosinophilic asthmasource ↗
▲Partnership / LicenseKT-200Corporate
Gilead exercises option to exclusively license KT-200
cancers with CCNE1 amplification/overexpressionsource ↗
▲Milestone PaymentKT-200Corporate
$45 million milestone payment triggered by Gilead option exercise
●IND Enabling CompleteKT-200Preclinical
Gilead to progress KT-200 into IND-enabling studies
cancers with CCNE1 amplification/overexpressionsource ↗
▲Fast Track DesignationKT-621Designation
FDA granted Fast Track designation for KT-621 in moderate to severe asthma
moderate to severe eosinophilic asthmasource ↗
▲Partnership / LicenseKT-200Corporate
Gilead exercised option to exclusively license KT-200
solid tumorssource ↗
▲Runway Guidance UpdateCorporate
Cash runway into 2029 with $1.55 billion as of March 31, 2026
▲Oral PresentationKT-621Presentation
Late-breaking oral presentation of Phase 1b BroADen trial results at AAD 2026
atopic dermatitissource ↗
▲Oral PresentationKT-621Presentation
Late-breaking oral presentation of positive Phase 1b atopic dermatitis results at AAD Annual Meeting
atopic dermatitissource ↗
▲Full ResultsKT-621Clinical Data
Positive results from KT-621 Phase 1b AD trial presented at AAD Annual Meeting
atopic dermatitissource ↗
▲Trial InitiationKT-621Trial
KT-621 BROADEN2 Phase 2b trial in atopic dermatitis ongoing
atopic dermatitissource ↗
▲First Patient DosedKT-579Trial
Initiated dosing in KT-579 Phase 1 healthy volunteer trial
healthy volunteerssource ↗
Past FDA Catalysts and PDUFA Decisions
How KYMR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-08 | KT-621 | Phase 1b data presentation | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C52 / 100
Pipeline Score
$1.3B
Pipeline Value
Richly Valued
Valuation Signal
6
Drugs Scored
0.1x
rNPV / MCap
Top 15%
Small Cap(rank 100 of 660)
Percentile Rank
Kymera Therapeutics, Inc. carries a moderate pipeline score (52/100), with $1.9B risk-adjusted pipeline value, led by KT-621 in Asthma (Diagnosis) (Phase 2), across $92B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KT-621 Small moleculeNCT07217015 | Atopic Dermatitis | Phase 2 | ACTIVE NOT_RECRUITING | 222 | Jun 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every KYMR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| KT-621 Fast Track | atopic dermatitis | Phase 1b | 2026-09-01 | deep STAT6 degradation in blood and skin; robust reductions in disease-relevant Type 2 inflammatory biomarkers; meaningful improvements on clinical endpoints and patient-reported outcomesRead More | Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology CongressesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mainolfi NelloDirector, Officer (Chief Executive Officer) | Option | 30,000 696,568 held | $2.08 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KYMR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 5 % (22 %) | 992.73 M | 8.66 M |
KYMR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KYMR ranks across every disease it competes in
Competitive Position is a premium feature
See how KYMR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKYMR News
KYMRKymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Citi Biopharma Summit. These events will feature fireside chats and presentations, allowing the company to highlight its innovative work in targeted protein degradation for immunological diseases. Live webcasts will be available for those unable to attend in person.
Read more →KYMRKymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Kymera Therapeutics has completed enrollment in its KT-621 BROADEN2 Phase 2b trial for atopic dermatitis, with topline data anticipated by the end of 2026. The company will present findings from the BroADen Phase 1b trial at upcoming European congresses. KT-621 is also undergoing evaluation in a Phase 2b asthma trial, with results expected in late 2027.
Read more →KYMRKymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported its Q2 2026 financial results, highlighting the rapid completion of enrollment in the KT-621 BROADEN2 Phase 2b trial for atopic dermatitis, six months ahead of schedule. The company has a robust cash position of $1.5 billion, supporting its pipeline, which includes ongoing trials for KT-621, KT-579, and partnered programs with Sanofi and Gilead. Upcoming milestones include data readouts expected by the end of 2026 and mid-2027.
Read more →KYMRKymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Kymera Therapeutics will report its second quarter 2026 financial results on August 5, 2026. The company is known for its innovative approach to developing oral small molecule degrader medicines aimed at treating immunological diseases. A video conference call will be held at 8:30 a.m. ET on the reporting day, with a replay available afterward.
Read more →KYMRKymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Kymera Therapeutics has appointed Dr. Terence Rooney as Chief Medical Officer, succeeding Dr. Jared Gollob, who is retiring. Dr. Rooney brings significant experience from Johnson & Johnson and will lead the clinical development strategy for Kymera's oral immunology portfolio. The company is positioned for growth with multiple clinical programs underway.
Read more →KYMRKymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics has appointed Dr. Elizabeth Laws as Senior Vice President and Global Program Team Leader for KT-621, a first-in-class oral STAT6 degrader. Dr. Laws, with over two decades of experience, will oversee the global development of KT-621, which is currently in Phase 2b trials for atopic dermatitis and asthma. The company anticipates data from these trials by late 2026 and mid-2027, respectively.
Read more →KYMR▲ +16.6%on this news
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics has completed enrollment in the BROADEN2 Phase 2b trial of KT-621 for atopic dermatitis, finishing nearly six months ahead of schedule. This allows for an earlier topline data readout expected by the end of 2026. The company plans to initiate Phase 3 trials by mid-2027, following positive interest and results from earlier studies.
Read more →KYMR▲ +16.6%on this newsshared move
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics has appointed Felix J. Baker, Ph.D., as the new Chairman of the Board, succeeding Bruce Booth, who will remain as an Independent Director. Dr. Baker, who has been with the board since 2024, brings valuable experience in scaling innovative companies. The company aims to enhance its oral small molecule degrader pipeline to improve treatment options for patients.
Read more →KYMRKymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Kymera Therapeutics presented Phase 1 data for KT-621, an oral STAT6 degrader, at the JDA Annual Meeting. The study in healthy Japanese adults showed consistent safety and pharmacokinetic results with previous trials. KT-621 is currently undergoing parallel Phase 2b trials for atopic dermatitis and asthma, with data expected by mid-2027 and late 2027, respectively.
Read more →KYMRKymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Kymera Therapeutics has initiated a Phase 1 trial for KT-485, an oral IRAK4 degrader, with the first participant dosed. This milestone has triggered a $20 million payment from Sanofi, who is leading the trial. The study aims to evaluate the drug's safety and pharmacokinetics, with potential for significant future milestone payments.
Read more →KYMRKymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Read more →KYMRKymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Kymera Therapeutics has appointed Penny Carlson as Senior Vice President of Development Operations. Carlson, with over 20 years of experience, will lead global clinical development operations for the company's oral immunology portfolio. This transition comes as Jeremy Chadwick retires from his role as COO but will remain as an advisor. Carlson's expertise is expected to significantly contribute to advancing Kymera's pipeline.
Read more →KYMRKymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Kymera Therapeutics will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The event will be held in New York and will feature a live webcast available on the company's website. Kymera is focused on developing innovative oral small molecule degrader medicines for immunological diseases.
Read more →KYMRKymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Kymera Therapeutics announced significant findings from the BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader, during presentations at the SID and ATS congresses. The data indicate robust STAT6 degradation and reductions in Type 2 inflammatory biomarkers, supporting KT-621's potential for treating atopic dermatitis and asthma. Ongoing Phase 2b trials aim to validate these findings further, with results anticipated by mid-2027.
Read more →KYMRKymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences: the Bank of America 2026 Healthcare Conference on May 12 and the RBC Capital Markets 2026 Global Healthcare Conference on May 19. Live webcasts of the presentations will be available on the company's website, with replays archived post-event. Kymera is focused on developing innovative therapies for immunological diseases.
Read more →KYMRKymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Kymera Therapeutics has presented promising preclinical data for KT-579, a first-in-class oral IRF5 degrader, at Digestive Disease Week 2026. The data indicate that KT-579 demonstrates significant disease-modifying activity in inflammatory bowel disease (IBD) models, showing potential to outperform existing therapies. The ongoing Phase 1 trial aims to evaluate the safety and effectiveness of KT-579, with results expected in the second half of 2026. The findings suggest that KT-579 could transform treatment for complex autoimmune diseases by targeting multiple inflammatory pathways.
Read more →KYMRKymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported its Q1 2026 financial results, highlighting ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma. The FDA granted Fast Track designation for KT-621 in asthma, while the company maintains a strong cash position of $1.55 billion. Positive data from KT-621's Phase 1b trial was presented at a major dermatology conference. However, the company reported a net loss of $69.2 million for the quarter.
Read more →KYMRKymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will report its first quarter 2026 financial results on April 30, 2026. The company is known for developing oral small molecule degrader medicines aimed at immunological diseases. A video conference call and webcast will be held at 8:30 a.m. ET on the same day.
Read more →KYMRKymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Kymera Therapeutics announced that the FDA has granted Fast Track designation for KT-621, a first-in-class oral STAT6 degrader aimed at treating moderate to severe eosinophilic asthma. This designation allows for closer collaboration with the FDA to expedite development. KT-621 is currently undergoing two Phase 2b trials, with data expected in 2027. The drug aims to provide a convenient oral alternative for asthma patients who currently have limited options.
Read more →KYMRKymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Kymera Therapeutics announced that Gilead Sciences has exercised its option to license KT-200, a novel oral CDK2 molecular glue degrader. This action triggers a $45 million milestone payment to Kymera. Gilead plans to advance KT-200 into IND-enabling studies for a potential IND filing in 2027. The drug shows promise in treating challenging cancers, particularly those with CDK2 involvement.
Read more →About Kymera Therapeutics, Inc.
Headquarters500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE PLUS
Trade the next KYMR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime